Morie Gertz

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. doi request reprint Waldenström macroglobulinemia: 2013 update on diagnosis, risk stratification, and management
    Morie A Gertz
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Am J Hematol 88:703-11. 2013
  2. doi request reprint Immunoglobulin light chain amyloidosis: 2013 update on diagnosis, prognosis, and treatment
    Morie A Gertz
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Am J Hematol 88:416-25. 2013
  3. doi request reprint Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis
    M A Gertz
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Bone Marrow Transplant 48:557-61. 2013
  4. doi request reprint Waldenström macroglobulinemia: my way
    Morie Gertz
    Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Leuk Lymphoma 54:464-71. 2013
  5. doi request reprint Stem cell transplant for Waldenström macroglobulinemia: an underutilized technique
    M A Gertz
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Bone Marrow Transplant 47:1147-53. 2012
  6. doi request reprint Waldenström macroglobulinemia
    Morie A Gertz
    Division of Hematology, Mayo Clinic, 200 First Street, SW, Siebens 667, Rochester, MN 55905, USA
    Hematology 17:S112-6. 2012
  7. doi request reprint Waldenström macroglobulinemia: 2012 update on diagnosis, risk stratification, and management
    Morie A Gertz
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Am J Hematol 87:503-10. 2012
  8. ncbi request reprint Immunoglobulin light-chain amyloidosis: growing recognition, new approaches to therapy, active clinical trials
    Morie A Gertz
    Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Oncology (Williston Park) 26:152-61. 2012
  9. doi request reprint How to manage primary amyloidosis
    M A Gertz
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 26:191-8. 2012
  10. doi request reprint Immunoglobulin D amyloidosis: a distinct entity
    Morie A Gertz
    Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Blood 119:44-8. 2012

Detail Information

Publications144 found, 100 shown here

  1. doi request reprint Waldenström macroglobulinemia: 2013 update on diagnosis, risk stratification, and management
    Morie A Gertz
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Am J Hematol 88:703-11. 2013
    ..Waldenström macroglobulinemia (WM) is a lymphoplasmacytic lymphoma with immunoglobulin M (IgM) monoclonal protein. Clinical features include anemia, thrombocytopenia, hepatosplenomegaly, and lymphadenopathy...
  2. doi request reprint Immunoglobulin light chain amyloidosis: 2013 update on diagnosis, prognosis, and treatment
    Morie A Gertz
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Am J Hematol 88:416-25. 2013
    ..Clinical features depend on organs involved but can include restrictive cardiomyopathy, nephrotic syndrome, hepatic failure, peripheral/autonomic neuropathy, and atypical multiple myeloma...
  3. doi request reprint Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis
    M A Gertz
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Bone Marrow Transplant 48:557-61. 2013
    ..Patients with serum troponin T >0.06 ng/mL or NT-proBNP >5000 pg/mL (not on dialysis) should not be considered candidates for SCT because of early mortality...
  4. doi request reprint Waldenström macroglobulinemia: my way
    Morie Gertz
    Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Leuk Lymphoma 54:464-71. 2013
    ..The current preferred Mayo Clinic non-study treatment is rituximab, cyclophosphamide, and dexamethasone. The median survival associated with this disease is now over 10 years...
  5. doi request reprint Stem cell transplant for Waldenström macroglobulinemia: an underutilized technique
    M A Gertz
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Bone Marrow Transplant 47:1147-53. 2012
    ..Allogeneic transplant should be considered investigational and used only in the context of a clinical trial or when other chemotherapeutic options have been exhausted...
  6. doi request reprint Waldenström macroglobulinemia
    Morie A Gertz
    Division of Hematology, Mayo Clinic, 200 First Street, SW, Siebens 667, Rochester, MN 55905, USA
    Hematology 17:S112-6. 2012
    ..The current preferred Mayo Clinic non-study treatment is rituximab, cyclophosphamide, and dexamethasone. The median survival associated with this disease is now over 10 years...
  7. doi request reprint Waldenström macroglobulinemia: 2012 update on diagnosis, risk stratification, and management
    Morie A Gertz
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Am J Hematol 87:503-10. 2012
    ..Waldenström macroglobulinemia (WM) is a lymphoplasmacytic lymphoma with immunoglobulin M (IgM) monoclonal protein. Clinical features include anemia, thrombocytopenia, hepatosplenomegaly, and lymphadenopathy...
  8. ncbi request reprint Immunoglobulin light-chain amyloidosis: growing recognition, new approaches to therapy, active clinical trials
    Morie A Gertz
    Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Oncology (Williston Park) 26:152-61. 2012
    ..Despite advances in the past decade, 30% of patients still die within a year of diagnosis, suggesting that failure to recognize this disorder prior to advanced organ dysfunction remains a major impediment to improving outcomes...
  9. doi request reprint How to manage primary amyloidosis
    M A Gertz
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 26:191-8. 2012
    ..Early mortality rates remain high. Effective chemotherapy can result in reversal of organ dysfunction and recovery. Reductions in light chain production translate to improved survival...
  10. doi request reprint Immunoglobulin D amyloidosis: a distinct entity
    Morie A Gertz
    Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Blood 119:44-8. 2012
    ..The overall survival of these patients does not appear to be different from that of patients who have light-chain amyloidosis associated with another monoclonal protein...
  11. ncbi request reprint When is myeloma, myeloma?
    Morie A Gertz
    Mayo Clinic, Department of Hematology, Rochester, MN 55905, USA
    Leuk Lymphoma 47:1452-3. 2006
  12. ncbi request reprint Myeloablative chemotherapy and stem cell transplantation in myeloma or primary amyloidosis with renal involvement
    Morie A Gertz
    Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Kidney Int 68:1464-71. 2005
    ....
  13. doi request reprint Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidney
    Morie A Gertz
    Division of Hematology, Mayo Clinic, Rochester, MN, USA
    Nephrol Dial Transplant 24:3132-7. 2009
    ..The kidney is affected by immunoglobulin light chain amyloidosis (AL) in more than 50% of patients who present with the disease, but long-term predictors for and outcomes after renal replacement therapy are not well described...
  14. pmc Clinical value of minor responses after 4 doses of rituximab in Waldenström macroglobulinaemia: a follow-up of the Eastern Cooperative Oncology Group E3A98 trial
    Morie A Gertz
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Br J Haematol 147:677-80. 2009
    ..Future studies of Waldenström macroglobulinaemia should report minor responses because they are associated with clinically meaningful benefits. This trial was registered at http://www.clinicaltrials.gov as #NCT00005609...
  15. ncbi request reprint Amyloidosis
    Morie A Gertz
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Best Pract Res Clin Haematol 18:709-27. 2005
    ..This paper reviews a diagnostic pathway clinicians can use to diagnose the disorder, assess a patient's prognosis, and logically plan a therapeutic strategy...
  16. pmc Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy
    Morie A Gertz
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Blood 106:2837-40. 2005
    ..The presence of t(4;14) identifies a subset of patients whose time to progression is only 8.2 months. These patients receive minimal benefit from autologous stem cell transplantation and are candidates for novel therapeutic approaches...
  17. ncbi request reprint Managing myeloma of the kidney
    Morie A Gertz
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Leuk Lymphoma 48:221-2. 2007
  18. doi request reprint Stem cell transplantation in multiple myeloma: impact of response failure with thalidomide or lenalidomide induction
    Morie A Gertz
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Blood 115:2348-53; quiz 2560. 2010
    ..5 vs 30.4 months) and a shorter progression-free survival (22.1 vs 13.1 months; P < .001). Absence of a response to induction therapy with thalidomide or lenalidomide predicts a poorer outcome after high-dose therapy...
  19. ncbi request reprint Waldenström macroglobulinemia: a review of therapy
    Morie A Gertz
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Hematol 79:147-57. 2005
    ....
  20. ncbi request reprint What is the correct philosophy for the treatment of multiple myeloma?
    Morie A Gertz
    Department of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Leuk Lymphoma 48:2298-9. 2007
  21. ncbi request reprint Relevant prognostic features of multiple myeloma and the new International Staging System
    Morie A Gertz
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Leuk Lymphoma 48:458-68. 2007
    ..This review describes development of the International Staging System and details prognostic factors that may further our understanding of the biology of multiple myeloma...
  22. doi request reprint Transplantation for IgM amyloidosis and IgM myeloma
    Morie A Gertz
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Clin Lymphoma Myeloma 9:77-9. 2009
    ..IgM patients are older, and the amyloidosis cohort has a higher incidence of neuropathy and lower incidence of cardiac involvement by echocardiography and troponin T level...
  23. doi request reprint New targets and treatments in multiple myeloma: Src family kinases as central regulators of disease progression
    Morie A Gertz
    Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Leuk Lymphoma 49:2240-5. 2008
    ..This review will focus in particular on Src-dependent signalling pathways, reflecting the expanding realisation of the critical and ubiquitous role of Src family kinases (SFKs) in normal and abnormal hematopoiesis...
  24. ncbi request reprint Transplantation without growth factor: engraftment kinetics after stem cell transplantation for primary systemic amyloidosis (AL)
    M A Gertz
    Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Bone Marrow Transplant 40:989-93. 2007
    ..Non-staphylococcal bacteremia was detected in 16% of patients. The median hospital stay was 9 days. It is feasible and reasonable to withhold growth factor therapy after autologous stem cell transplantation in patients with AL...
  25. ncbi request reprint Managing monoclonal gammopathy-associated neuropathy
    Morie A Gertz
    Division of Hematology, Mayo Clinic, College of Medicine, Rochester, MN 55905, USA
    Leuk Lymphoma 47:785-6. 2006
  26. doi request reprint Troponin T level as an exclusion criterion for stem cell transplantation in light-chain amyloidosis
    Morie Gertz
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Leuk Lymphoma 49:36-41. 2008
    ..Those with troponin T levels exceeding 0.06 microg/L should be considered for less toxic therapies until the clinically optimal use of stem cell transplantation is better defined by randomized clinical trials...
  27. doi request reprint Troponin in hematologic oncology
    Morie A Gertz
    Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Leuk Lymphoma 49:194-203. 2008
    ....
  28. doi request reprint Long-term risk of myelodysplasia in melphalan-treated patients with immunoglobulin light-chain amyloidosis
    Morie A Gertz
    Department of Hematology, Mayo Clinic, 200 First Street SW, Rochester MN, 55905, USA
    Haematologica 93:1402-6. 2008
    ..The actuarial risk of myelodysplasia development at ten years was 18%. As the survival of patients with plasma cell disorders improves, myelodysplasia may be a more common cause of morbidity and mortality for this group...
  29. ncbi request reprint Effect of hematologic response on outcome of patients undergoing transplantation for primary amyloidosis: importance of achieving a complete response
    Morie A Gertz
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Haematologica 92:1415-8. 2007
    ..001), even after eliminating bias from early death. The degree of response was affected by the intensity of chemotherapy conditioning, septal thickness, and cardiac biomarkers. Hematologic response translates to longer survival...
  30. doi request reprint Autologous stem cell transplant in 716 patients with multiple myeloma: low treatment-related mortality, feasibility of outpatient transplant, and effect of a multidisciplinary quality initiative
    Morie A Gertz
    Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 83:1131-8. 2008
    ..The overall 100-day survival rate was 98.9%. Our experience shows that outpatient transplant is feasible for all patients with multiple myeloma and results in shorter hospital stays and low treatment-related mortality rates...
  31. ncbi request reprint Management of cold haemolytic syndrome
    Morie A Gertz
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Br J Haematol 138:422-9. 2007
    ..This review of cold haemolytic syndromes describes new therapies and clinical strategies to determine a correct diagnosis...
  32. ncbi request reprint Transplantation for amyloidosis
    Morie A Gertz
    Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Curr Opin Oncol 19:136-41. 2007
    ..We describe nearly 300 patients who had treatment combining high-dose chemotherapy and stem cell transplantation at Mayo Clinic and review the recent literature...
  33. pmc Comparison of high-dose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myeloma
    M A Gertz
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Bone Marrow Transplant 43:619-25. 2009
    ..Our data suggested that CY damaged the microenvironment and slowed engraftment. By lengthening the period between the completion of apheresis and stem cell reinfusion, the microenvironment may recover and result in faster engraftment...
  34. ncbi request reprint Current status of stem cell transplantation for multiple myeloma
    Morie A Gertz
    Division of Hematology and Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Curr Treat Options Oncol 6:229-40. 2005
    ..Whether the new agents thalidomide, lenalidomide, and bortezomib will have an impact on the survival advantage of stem cell transplantation is unknown...
  35. ncbi request reprint Caring (really) for patients who use alternative therapies for cancer
    Morie A Gertz
    Division of Hematology and Internal Medicine and Area General Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 21:125s-128s. 2003
  36. doi request reprint Clinical impact and resource utilization after stem cell mobilization failure in patients with multiple myeloma and lymphoma
    M A Gertz
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Bone Marrow Transplant 45:1396-403. 2010
    ..This usually unappreciated resource utilization associated with stem cell mobilization failure highlights the need for more effective mobilization strategies...
  37. ncbi request reprint Therapy for immunoglobulin light chain amyloidosis: the new and the old
    Morie A Gertz
    Division of Hematology and Internal Medicine, Mayo Clinic, 200 First Street, SW, Rochester, MN 55905, USA
    Blood Rev 18:17-37. 2004
    ..Systemic chemotherapy would not be expected to have any beneficial effect on other forms of amyloid and carries significant risk...
  38. ncbi request reprint Treatment of immunoglobulin light chain (primary or AL) amyloidosis
    Morie A Gertz
    Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Oncology (Williston Park) 25:620-6. 2011
    ..The role of the recently introduced novel agents in management of amyloidosis is also reviewed...
  39. doi request reprint Waldenström macroglobulinemia: 2011 update on diagnosis, risk stratification, and management
    Morie A Gertz
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Am J Hematol 86:411-6. 2011
    ..Waldenström macroglobulinemia (WM) is a lymphoplasmacytic lymphoma with immunoglobulin M (IgM) monoclonal protein. Clinical features include anemia, thrombocytopenia, hepatosplenomegaly, and lymphadenopathy...
  40. ncbi request reprint Waldenström's macroglobulinemia
    M A Gertz
    Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Oncologist 5:63-7. 2000
    ..The median survival of symptomatic patients is 65 months. Patients without symptoms should not be treated...
  41. ncbi request reprint A multicenter phase 2 trial of stem cell transplantation for immunoglobulin light-chain amyloidosis (E4A97): an Eastern Cooperative Oncology Group Study
    M A Gertz
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Bone Marrow Transplant 34:149-54. 2004
    ..3 months. Median survival has not been reached. Stem cell transplantation for selected patients with amyloidosis is feasible in a cooperative group setting. A multicenter phase 3 trial of high-dose therapy is indicated...
  42. doi request reprint IgM amyloidosis: clinical features in therapeutic outcomes
    Morie A Gertz
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Clin Lymphoma Myeloma Leuk 11:146-8. 2011
    ..IgM patients are older, have a higher prevalence of neuropathy, a lower incidence of cardiac involvement (lower troponin T and NT-proBNP), and a much lower level of the involved immunoglobulin free light chain...
  43. doi request reprint Current status of stem cell mobilization
    Morie A Gertz
    Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Br J Haematol 150:647-62. 2010
    ..Specific recommendations for patients who are poor mobilizers are dealt with including the role of plerixafor...
  44. doi request reprint SCT without growth factor in multiple myeloma: engraftment kinetics, bacteremia and hospitalization
    M A Gertz
    Division of Hematology, Rochester, MN 55905, USA
    Bone Marrow Transplant 46:956-61. 2011
    ..The median hospital stay was 3.5 days shorter in the group not receiving growth factor. It is feasible and reasonable to perform autologous SCT for multiple myeloma without administering growth factors...
  45. doi request reprint Autologous stem cell transplant for immunoglobulin light chain amyloidosis: a status report
    Morie A Gertz
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Leuk Lymphoma 51:2181-7. 2010
    ..001). The only predictor of survival was cardiac stage (p  < 0.001). The hematologic response rate is predictive for organ response rates. Both hematologic and organ responses are associated with improved survival...
  46. ncbi request reprint Primary systemic amyloidosis
    Morie A Gertz
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Curr Treat Options Oncol 3:261-71. 2002
    ..Transplant is associated with unique morbidities not seen in the transplantation of patients with other hematologic malignancies...
  47. ncbi request reprint Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate
    M A Gertz
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Bone Marrow Transplant 34:1025-31. 2004
    ..Methods are needed to reduce treatment-related toxicity so that more patients can receive full-dose conditioning chemotherapy...
  48. doi request reprint Systemic amyloidosis associated with chronic lymphocytic leukemia/small lymphocytic lymphoma
    Taxiarchis V Kourelis
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Am J Hematol 88:375-8. 2013
    ..Distinguishing between these two groups is essential since patients with non-AL amyloidosis have better outcomes and they do not require cytotoxic chemotherapy to treat their amyloidosis...
  49. ncbi request reprint Cyclophosphamide mobilization does not improve outcome in patients receiving stem cell transplantation for multiple myeloma
    David Dingli
    Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Clin Lymphoma Myeloma 6:384-8. 2006
    ..The impact of cyclophosphamide on CR rates and TTP was evaluated...
  50. ncbi request reprint Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia
    Morie A Gertz
    Mayo Clinic, Rochester, MN, USA
    Semin Oncol 30:121-6. 2003
    ..11) Corticosteroids may be useful in the treatment of symptomatic mixed cryoglobulinemia. (12) Splenectomy is rarely indicated but has been used to manage painful splenomegaly and hypersplenism...
  51. pmc Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients
    Francesca Gay
    Department of Internal Medicine, Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Blood 115:1343-50. 2010
    ..3% vs 9.2%, P = .058) and peripheral neuropathy (10.4% vs 0.9%, P < .001). Len/dex appears well-tolerated and more effective than thal/dex. Randomized trials are needed to confirm these results...
  52. ncbi request reprint Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial
    David Dingli
    Division of Hematology, Department of Internal Medicine, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Haematologica 90:1650-4. 2005
    ..We present the first data on the outcome of patients with newly diagnosed multiple myeloma treated with Thal/Dex who did not undergo upfront ASCT...
  53. doi request reprint Long-term outcomes after autologous stem cell transplantation for patients with POEMS syndrome (osteosclerotic myeloma): a single-center experience
    Anita D'Souza
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood 120:56-62. 2012
    ..Most patients could be salvaged with immunomodulatory drugs or radiation. The 5-year survival is 94%. Herein, we describe a system of monitoring response and progression among patients with POEMS after ASCT...
  54. ncbi request reprint Natural history and therapy of 66 patients with mixed cryoglobulinemia
    Alan H Bryce
    Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Hematol 81:511-8. 2006
    ..Treatment is generally directed at the underlying condition. Not all patients require treatment, and many can be followed and treated symptomatically...
  55. ncbi request reprint Myeloma and the newly diagnosed patient: a focus on treatment and management
    S Vincent Rajkumar
    Mayo Medical School, 200 First Street SW, Rochester, MN 55905, USA
    Semin Oncol 29:5-10. 2002
    ..The role of supportive care strategies for patients with bone disease, such as the use of bisphosphonates, is also discussed...
  56. doi request reprint Long-term outcome of autologous stem cell transplantation in light chain deposition disease
    Elizabeth C Lorenz
    Division of Nephrology and Hypertension, Mayo Clinic, 200 1st Street SW, Rochester, MN 55905, USA
    Nephrol Dial Transplant 23:2052-7. 2008
    ..However, the impact of ASCT on renal function is unclear. This study retrospectively reviewed the effect of ASCT on renal function in patients with LCDD...
  57. pmc Urinary albumin excretion patterns of patients with cast nephropathy and other monoclonal gammopathy-related kidney diseases
    Nelson Leung
    Division of Hematology, Mayo Clinic, Rochester, Minnesota 55901, USA
    Clin J Am Soc Nephrol 7:1964-8. 2012
    ....
  58. ncbi request reprint Two-dimensional acoustic pattern derived strain parameters closely correlate with one-dimensional tissue Doppler derived strain measurements
    Karen M Modesto
    Division of Cardiology, Mayo Clinic College of Medicine, Rochester, MN, USA
    Eur J Echocardiogr 7:315-21. 2006
    ..Novel 2D-SE software allows semi-automated strain measurements and increased averaging capabilities optimizing signal-noise ratio...
  59. ncbi request reprint Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling
    Wee J Chng
    Department of Hematology Oncology, Mayo Clinic, Scottsdale, Arizona, USA
    Cancer Res 67:2982-9. 2007
    ..Furthermore, the signatures that defined these clusters may provide a basis for tailoring treatment to individual patients...
  60. pmc Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone
    Prashant Kapoor
    Department of Internal Medicine, Division of Hematology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Blood 114:518-21. 2009
    ..These results need confirmation in larger, prospectively designed studies...
  61. pmc Long-term results of single-agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myeloma
    Kristen Detweiler-Short
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Am J Hematol 85:737-40. 2010
    ..Grade 3-4 nonhematologic adverse events were noted in 55% of patients. Randomized trials are needed to determine the role of early therapy in SMM...
  62. ncbi request reprint Vascular abnormalities in primary amyloidosis
    Karen M Modesto
    Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USA
    Eur Heart J 28:1019-24. 2007
    ..Primary amyloidosis (AL) is a systemic disease; however, there is limited information regarding the presence and character of vascular abnormalities...
  63. ncbi request reprint Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma
    Shaji Kumar
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA
    Mayo Clin Proc 78:34-9. 2003
    ..To assess response rate, duration of response, progression-free survival, and toxicity of thalidomide in patients with relapsed multiple myeloma...
  64. ncbi request reprint Quantitative analysis of clonal bone marrow CD19+ B cells: use of B cell lineage trees to delineate their role in the pathogenesis of light chain amyloidosis
    Michelle K Manske
    Division of Hematology, Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Clin Immunol 120:106-20. 2006
    ..These data provide a robust example of the use of graphical quantification methods in delineating the role of neoplastic precursors in the pathogenesis of hematopoietic malignancies...
  65. pmc Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification system
    David Dingli
    Division of Hematology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Blood 107:3384-8. 2006
    ..4, and 6.5 months, respectively. CMCs at the time of ASCT is an independent prognostic factor and in combination with cytogenetics provides a powerful scoring system that stratifies patients and guides management...
  66. ncbi request reprint Prognostic value of angiogenesis in solitary bone plasmacytoma
    Shaji Kumar
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood 101:1715-7. 2003
    ..02). Angiogenesis is increased in solitary plasmacytoma and is a significant predictor of progression to myeloma and provides further evidence of its importance in the pathogenesis of myeloma...
  67. doi request reprint Exploring the amyloid proteome in immunoglobulin-derived lymph node amyloidosis using laser microdissection/tandem mass spectrometry
    Anita D'Souza
    Division of Hematology, Mayo Clinic, Rochester, Minnesota Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota
    Am J Hematol 88:577-80. 2013
    ..19 months, P = 0.06) was seen. Mass spectrometric amyloid analysis is a powerful tool for characterizing amyloid and may provide additional prognostic information...
  68. doi request reprint Case vignettes and other brain teasers of monoclonal gammopathies
    Morie Gertz
    Department of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Hematology Am Soc Hematol Educ Program 2012:582-5. 2012
    ....
  69. doi request reprint Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management
    R A Kyle
    Division of Hematology, Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 24:1121-7. 2010
    ..Testing should be done 2-3 months after the initial recognition of SMM. If the results are stable, the patient should be followed every 4-6 months for 1 year and, if stable, every 6-12 months...
  70. doi request reprint Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma
    Francesca Gay
    Division of Hematology, Department of Internal Medicine, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Am J Hematol 85:664-9. 2010
    ..5% vs. 4.2%, P = 0.129) were higher with Rd. Results of this case-matched analysis suggest that there is significant additive value when clarithromycin is added to Rd. Randomized phase III trials are needed to confirm these results...
  71. pmc Clinical features and treatment response of light chain (AL) amyloidosis diagnosed in patients with previous diagnosis of multiple myeloma
    Sumit Madan
    Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 85:232-8. 2010
    ..To identify and assess the clinical features and treatment response of light chain (AL) amyloidosis diagnosed in patients with previous diagnosis of multiple myeloma (MM)...
  72. pmc Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapie
    Prashant Kapoor
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Mayo Clin Proc 85:532-7. 2010
    ..This study validates the high-risk features defined by FISH and CG in the Mayo risk-stratification model for patients with MM predominantly treated with novel therapies based on immunomodulatory agents...
  73. ncbi request reprint In vivo and in silico studies on single versus multiple transplants for multiple myeloma
    David Dingli
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Cancer Sci 98:734-9. 2007
    ..TTP after tandem transplants (with its higher associated mortality) cannot be superior to TTP achieved with optimally timed serial transplants. Individualized HDT-ASCT for patients with MM is possible and may optimize results...
  74. ncbi request reprint High-dose chemotherapy with autologous hematopoietic stem cell transplantation in patients with multiple myeloma
    Morie A Gertz
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Expert Rev Anticancer Ther 6:343-60. 2006
    ..Also of importance are prognosis, features that predict outcome, the suitability of transplant candidates, and post-transplantation maintenance therapy...
  75. pmc Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma
    Grzegorz S Nowakowski
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Blood 106:2276-9. 2005
    ..We conclude that the number of circulating PCs measured by flow cytometry in patients with newly diagnosed MM is an independent predictor of survival...
  76. ncbi request reprint Acquired Fanconi syndrome is an indolent disorder in the absence of overt multiple myeloma
    Cynthia X Ma
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood 104:40-2. 2004
    ..In conclusion, FS associated with monoclonal gammopathy does not appear to confer an additional risk of subsequent evolution to MM. ESRD occurs late in the disease process...
  77. ncbi request reprint Initial immunoglobulin M 'flare' after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia: an Eastern Cooperative Oncology Group Study
    Irene M Ghobrial
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA
    Cancer 101:2593-8. 2004
    ..The goal of the current study was to characterize the initial upsurge in immunoglobulin M (IgM) levels after treatment with rituximab in patients with Waldenstrom macroglobulinemia (WM)...
  78. doi request reprint Prediction of survival using absolute lymphocyte count for newly diagnosed patients with multiple myeloma: a retrospective study
    Hilmi Ege
    Division of Hematology Department of Medicine, Mayo Clinic College of Medicine, Rochester, MN, USA
    Br J Haematol 141:792-8. 2008
    ..This study showed that, in newly diagnosed MM, ALC is an independent prognostic factor for OS, suggesting a significant role of host immune status in the survival of MM...
  79. ncbi request reprint Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia
    Irene M Ghobrial
    Division of Hematology, Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Br J Haematol 133:158-64. 2006
    ..Beta2-microglobulin > or =4 mg/l was associated with a threefold increase in the risk of death when added to the prognostic model. We describe a simple prognostic model for overall survival for newly diagnosed patients with WM...
  80. doi request reprint Lenalidomide plus dexamethasone vs. lenalidomide plus melphalan and prednisone: a retrospective study in newly diagnosed elderly myeloma
    Francesca Gay
    Department of Internal Medicine, Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN, USA
    Eur J Haematol 85:200-8. 2010
    ..The goal of this retrospective study was to compare the efficacy and toxicity of lenalidomide-dexamethasone (len/dex) vs. melphalan-prednisone-lenalidomide (MPR) as upfront therapy for newly diagnosed elderly patients with myeloma...
  81. ncbi request reprint Primary (AL) hepatic amyloidosis: clinical features and natural history in 98 patients
    Miguel A Park
    Division of General Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Medicine (Baltimore) 82:291-8. 2003
    ..Liver biopsy was safe. Some patients benefit from systemic chemotherapy...
  82. ncbi request reprint Prognostic value of circulating plasma cells in monoclonal gammopathy of undetermined significance
    Shaji Kumar
    Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 23:5668-74. 2005
    ..Identification of patients with MGUS at high risk of progression will allow development of preventive strategies. We studied the prognostic value of circulating plasma cells (PCs) in patients with MGUS to predict progression...
  83. pmc Clinical implication of centrosome amplification in plasma cell neoplasm
    Wee J Chng
    Division of Hematology Oncology, Mayo Clinic, Johnson Research Bldg, 13400 E Shea Blvd, Scottsdale, AZ, USA
    Blood 107:3669-75. 2006
    ....
  84. ncbi request reprint Amyloidosis with IgM monoclonal gammopathies
    Morie A Gertz
    Dysproteinemia Clinic and the Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA
    Semin Oncol 30:325-8. 2003
    ..We conclude that the presence of amyloid cardiomyopathy and an increased creatinine concentration had the greatest impact on survival...
  85. ncbi request reprint Bone marrow angiogenesis in multiple myeloma: effect of therapy
    Shaji Kumar
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Br J Haematol 119:665-71. 2002
    ..We conclude that the degree of bone marrow angiogenesis is a prognostic marker in patients with multiple myeloma and does not decrease significantly after therapy...
  86. ncbi request reprint Waldenström's macroglobulinemia: a review of therapy
    Morie A Gertz
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Leuk Lymphoma 43:1517-26. 2002
    ..Treatment needs to be individualized based on patient age, the clinical manifestations of Waldenström's, and the patient's potential for developing toxic side effects of the selected treatment regimen...
  87. ncbi request reprint Circulating peripheral blood plasma cells as a prognostic indicator in patients with primary systemic amyloidosis
    Animesh Pardanani
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood 101:827-30. 2003
    ..008). The prognostic value of circulating PBPCs may help select treatment for patients with AL...
  88. doi request reprint The role of high-dose chemotherapy followed by peripheral blood stem cell transplantation for the treatment of multiple myeloma
    Mustaqeem Siddiqui
    Division of Hematology, Mayo Clinic, Rochester 55905, USA
    Leuk Lymphoma 49:1436-51. 2008
    ....
  89. pmc The importance of bone marrow examination in determining complete response to therapy in patients with multiple myeloma
    Cheng E Chee
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood 114:2617-8. 2009
    ..2 years vs 2.3 years, respectively; P = .01)...
  90. pmc Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component
    John A Lust
    Division of Hematology, Mayo Clinic, Rochester, MN 55905
    Mayo Clin Proc 84:114-22. 2009
    ..To conduct in vitro studies as well as a phase 2 clinical trial in patients with smoldering or indolent multiple myeloma to determine if interleukin 1 (IL-1) inhibitors can delay or prevent active myeloma...
  91. pmc Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs
    Angela Dispenzieri
    Department of Medicine, Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Am J Hematol 85:757-9. 2010
    ....
  92. pmc Serum immunoglobulin free light chain measurements and heavy chain isotype usage provide insight into disease biology in patients with POEMS syndrome
    Trista Stankowski-Drengler
    Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    Am J Hematol 85:431-4. 2010
    ..In summary, serum immunoglobulin profiles are unique in POEMS syndrome as compared with other plasma cell disorders...
  93. pmc Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score
    Shaji K Kumar
    Division of Hematology, Mayo Clinic, Rochester, MN 55905
    Mayo Clin Proc 86:12-8. 2011
    ..To examine whether the outcome of patients with primary systemic amyloidosis (AL) has improved over time and to identify predictors of early mortality in patients with AL...
  94. ncbi request reprint The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis
    Angela Dispenzieri
    Department of Biostatistics, Mayo Clinic, Rochester, MN 55905, USA
    Blood 109:465-70. 2007
    ..In AL patients, we saw limited activity of single-agent lenalidomide, but significant activity of the combination with dexamethasone, which warrants further investigation...
  95. pmc Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features
    Shaji Kumar
    Division of Hematology and Internal Medicine, Department of Laboratory Medicine and Pathology, Department of Biochemistry, Mayo Clinic, Rochester, MN, USA
    Blood 116:5126-9. 2010
    ..9 vs 37.1 months; P < .001. In multivariate analysis, dFLC was independent of other prognostic factors. The type of light chain impacts the spectrum of organ involvement and the FLC burden correlates with survival in AL...
  96. ncbi request reprint Review of 1027 patients with newly diagnosed multiple myeloma
    Robert A Kyle
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA
    Mayo Clin Proc 78:21-33. 2003
    ..To determine the clinical and laboratory features of newly diagnosed multiple myeloma...
  97. ncbi request reprint A multicenter phase II trial of 4'-iodo-4'deoxydoxorubicin (IDOX) in primary amyloidosis (AL)
    Morie A Gertz
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Amyloid 9:24-30. 2002
    ..4'-Iodo-4'-deoxydoxorubicin (IDOX) has been reported to bind to and lead to the catabolism of amyloid deposits. A multicenter study attempted to develop a dosing schedule to confirm those results...
  98. pmc Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines
    Stephen M Ansell
    Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 85:824-33. 2010
    ..Autologous stem cell transplant should be considered in all eligible patients with relapsed disease...
  99. ncbi request reprint Analysis of somatic hypermutation and antigenic selection in the clonal B cell in immunoglobulin light chain amyloidosis (AL)
    Roshini S Abraham
    Division of Hematology, Stabile 6 28, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    J Clin Immunol 24:340-53. 2004
    ..Additionally, mutational clusterspots were identified at specific positions in the nucleotide and deduced protein sequence that could potentially contribute to destabilizing interactions resulting in a propensity to form amyloid...
  100. pmc Peripheral blood stem cell transplant for POEMS syndrome is associated with high rates of engraftment syndrome
    Angela Dispenzieri
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Eur J Haematol 80:397-406. 2008
    ..Unraveling the mechanisms of the syndrome both in the context of ASCT and in general are challenges for the future...
  101. ncbi request reprint Functional gene expression analysis of clonal plasma cells identifies a unique molecular profile for light chain amyloidosis
    Roshini S Abraham
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Blood 105:794-803. 2005
    ..This study provides new insight into the molecular profile of clonal plasma cells and its functional relevance in the pathogenesis of light chain amyloidosis...

Research Grants6

  1. Phase 3 stem cell transplant for light chain amyloidosis
    Morie Gertz; Fiscal Year: 2005
    ..In addition, the analysis of clonal precursor B cells in the periphery and kinetics of amyloid formation of the monoclonal light chain will allow us to define and determine the mechanisms of disease progression and response to therapy. ..
  2. Phase 3 stem cell transplant for light chain amyloidosis
    Morie Gertz; Fiscal Year: 2007
    ..In addition, the analysis of clonal precursor B cells in the periphery and kinetics of amyloid formation of the monoclonal light chain will allow us to define and determine the mechanisms of disease progression and response to therapy. ..
  3. Phase 3 stem cell transplant for light chain amyloidosis
    Morie Gertz; Fiscal Year: 2009
    ..In addition, the analysis of clonal precursor B cells in the periphery and kinetics of amyloid formation of the monoclonal light chain will allow us to define and determine the mechanisms of disease progression and response to therapy. ..
  4. Phase 3 stem cell transplant for light chain amyloidosis
    Morie A Gertz; Fiscal Year: 2010
    ..In addition, the analysis of clonal precursor B cells in the periphery and kinetics of amyloid formation of the monoclonal light chain will allow us to define and determine the mechanisms of disease progression and response to therapy. ..
  5. Phase 3 stem cell transplant for light chain amyloidosis
    Morie A Gertz; Fiscal Year: 2011
    ..In addition, the analysis of clonal precursor B cells in the periphery and kinetics of amyloid formation of the monoclonal light chain will allow us to define and determine the mechanisms of disease progression and response to therapy. ..